About Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Biohaven Pharmaceutical Holding Co Ltd (BHVN) is a biopharmaceutical company specializing in the development and commercialization of innovative therapies to improve the lives of patients with neurological and neuropsychiatric diseases. The company was founded in 2013 and is headquartered in New Haven, Connecticut. Biohaven is focused on advancing its pipeline of novel drug candidates through clinical development and regulatory approval. The company's lead product candidate, rimegepant, is a small molecule calcitonin gene-related peptide receptor antagonist that is being evaluated for the acute treatment of migraine. Rimegepant has shown promising results in clinical trials and could potentially provide a new treatment option for the millions of patients who suffer from migraines.

In addition to rimegepant, Biohaven has a diverse portfolio of product candidates targeting other neurological disorders, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and generalized anxiety disorder (GAD). The company's pipeline also includes trigriluzole, an oral glutamate modulator, which is being investigated for the treatment of ALS and obsessive-compulsive disorder (OCD). Biohaven is committed to developing therapies that address significant unmet medical needs and has a strong scientific and clinical team dedicated to advancing its innovative pipeline of drug candidates.